Unlocking Competitive Advantage with the Top 10 Services You ...

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

In the high-stakes world of pharmaceutical development, the race to bring life-changing therapies to patients is more complex and competitive than ever. For decades, the industry operated on a relatively straightforward model: large pharmaceutical companies with sprawling internal R&D and manufacturing footprints would outsource tactical, non-core activities to Contract Manufacturing Organizations (CMOs). These CMOs were, in essence, a reliable “pair of hands,” providing capacity and executing well-defined processes. But the ground has shifted beneath our feet. The rise of biologics, the explosion of advanced modalities like cell and gene therapy, and the relentless pressure to accelerate timelines while managing costs have rendered this old model obsolete.

For more information, please visit Lianhe Aigen.

Welcome to the new paradigm. Today, the conversation is no longer about the CMO, but the Contract Development and Manufacturing Organization (CDMO). That single letter, “D” for Development, represents a seismic shift in the industry’s strategic calculus. The modern CDMO is not merely a service provider; it is an integrated strategic partner, an engine of innovation, and a critical component of a biopharma company’s ability to compete and succeed.1 They offer end-to-end solutions that span the entire lifecycle, from the earliest stages of process development to the complexities of commercial manufacturing and beyond.4

The sheer scale of this transformation is staggering. The global CDMO market, valued at over $238 billion in , is projected to surge to an astonishing $465 billion by , expanding at a compound annual growth rate (CAGR) of 9.0%. This isn’t just growth; it’s a fundamental restructuring of the pharmaceutical value chain. Why is this happening? The drivers are clear: outsourcing allows companies of all sizes to access specialized expertise they can’t afford to build in-house, accelerate development timelines, mitigate the immense financial risks of building dedicated facilities, and, most importantly, focus their precious capital and talent on their core competencies—drug discovery and clinical innovation.7

This shift is most pronounced among the small, virtual, and emerging biotech companies that are the lifeblood of our industry’s innovation. Lacking the vast infrastructure of Big Pharma, these companies are profoundly dependent on their CDMO partners.3 Yet, this creates a critical paradox: the very companies that rely most on these advanced services are often the least equipped to vet them. They know they need formulation development and cGMP manufacturing, but are they aware of the specialized capabilities that can de-risk their entire program, create new intellectual property, and build a durable competitive advantage?

This report is designed to bridge that knowledge gap. We will move beyond the well-understood, table-stakes services that every CDMO offers. Instead, we will pull back the curtain on the top 10 high-impact, strategic services that you, the biopharma leader, may not have known you needed. These are the capabilities that distinguish a tactical vendor from a true strategic partner. They are the services that can turn a challenging molecule into a blockbuster drug, navigate a complex regulatory pathway in record time, and maximize the value of your asset long after its initial approval. Understanding and leveraging these services is no longer a luxury; it is the blueprint for success in the new era of pharmaceutical development.

10 High-Impact CDMO Services to Supercharge Your Development Pipeline

In the modern biopharmaceutical landscape, the decision to outsource is no longer a simple make-versus-buy calculation. It’s a strategic choice that can define a program’s trajectory from the laboratory bench to the patient’s bedside. While standard offerings like API synthesis and fill-finish services are the bedrock of the CDMO industry, they represent commodity capabilities. True competitive advantage is found in a deeper, more specialized layer of services—capabilities that solve the industry’s most pressing challenges in formulation, manufacturing, regulation, and commercialization.

These are the services that enable the development of previously “undruggable” molecules, unlock new therapeutic modalities, and create durable market differentiation. They require a level of scientific expertise, technological investment, and regulatory acumen that is simply out of reach for most individual drug developers. By partnering with a CDMO that has mastered these high-impact capabilities, a biopharma company can effectively “rent” a world-class R&D and manufacturing engine, transforming its risk profile and accelerating its path to value creation.

The following sections provide an in-depth analysis of ten such services. We will explore the technical underpinnings of each, dissect their strategic business value, and provide a framework for identifying the right CDMO partner. For a quick overview, the table below summarizes these game-changing capabilities.

Table 1: The Top 10 High-Value CDMO Services at a Glance

1. Advanced Therapy Manufacturing: Mastering Cell & Gene Therapies (CGT)

We are in the midst of a therapeutic revolution. Cell and gene therapies (CGTs) are no longer the stuff of science fiction; they are a clinical reality, offering the potential for durable, and in some cases curative, treatments for cancers, genetic disorders, and other previously intractable diseases.11 This promise has ignited a firestorm of investment and research, propelling the CGT market into an explosive growth trajectory. Projections indicate the cell and gene therapy CDMO market alone will skyrocket from approximately $6.4 billion in to over $75 billion by , boasting a breathtaking CAGR of nearly 28%.13

But this revolution comes with a formidable challenge. The very complexity that makes these therapies so powerful also makes them extraordinarily difficult to manufacture. Unlike a traditional small molecule synthesized in a reactor, a cell therapy is a living drug. Its production involves intricate biological processes, requires an unprecedented level of quality control, and faces logistical hurdles that can seem insurmountable.11 This has created a critical manufacturing bottleneck that threatens to slow the entire field. For the vast majority of companies in this space, developing a CGT without a world-class CDMO partner is not just difficult; it’s virtually impossible.

The Foundational Role of a CGT CDMO

A true CGT CDMO offers far more than just bioreactor capacity. They provide an integrated ecosystem of technologies and expertise essential for translating a laboratory-scale concept into a robust, scalable, and commercially viable therapy. This is because, for biologics and especially for cell therapies, the regulatory mantra “the process is the product” holds absolute truth. The way a cell therapy is manufactured—the media used, the method of genetic modification, the expansion protocol—fundamentally defines the final therapeutic’s safety and efficacy profile.

This reality reframes the role of the CDMO from a mere contractor to a true co-developer. The process development choices made by the CDMO become integral to the drug’s Critical Quality Attributes (CQAs). A drug sponsor isn’t just outsourcing manufacturing; they are entrusting a core part of their product’s very identity to their partner. This elevates the partner selection process from a simple procurement decision to one of the most critical strategic choices a CGT company will make. The service you didn’t know you needed is a partner who can co-develop a commercially viable process from the ground up, not just execute a tech transfer of an academic, lab-scale procedure.

Core Capability 1: Viral Vector Development and Manufacturing

For a vast number of gene therapies and many cell therapies (like CAR-T), viral vectors are the essential delivery vehicle used to carry genetic material into cells. Manufacturing these vectors at clinical and commercial scale is a highly specialized discipline in its own right. A leading CDMO must have deep expertise in the two most common types:

• Adeno-Associated Virus (AAV): The workhorse for many in vivo gene therapies, prized for its safety profile.
• Lentivirus (LV): Commonly used for ex vivo cell therapies like CAR-T, capable of integrating its genetic payload into the host cell’s genome.

The manufacturing process is a multi-stage challenge involving plasmid DNA production, cell culture (historically in adherent systems like cell factories, but increasingly in more scalable suspension bioreactors), transfection, and a complex downstream purification process to separate full, potent viral particles from empty capsids and other impurities.17 CDMOs like Thermo Fisher Scientific and AGC Biologics have invested heavily in creating end-to-end platforms, such as ProntoLVV™ and BravoAAV™, that offer templated, optimized processes to accelerate timelines for clients.17

Core Capability 2: Autologous and Allogeneic Cell Therapy Production

The production of the cell therapy itself presents another layer of complexity, which differs dramatically depending on the therapeutic approach:

• Autologous Therapies: These are the ultimate personalized medicines, where a patient’s own cells are harvested, engineered, and re-infused. The “vein-to-vein” model of therapies like CAR-T is a logistical and manufacturing marvel. Each patient represents a single, unique batch (“N-of-1”). This model demands an unbreakable chain of custody and chain of identity to ensure the right cells return to the right patient.21 The manufacturing process—involving steps like leukapheresis, T-cell isolation, activation, transduction with a viral vector, cell expansion, and cryopreservation—must be performed with flawless execution to produce a viable, potent dose within a tight timeframe for a critically ill patient.
• Allogeneic Therapies: Hailed as the future of cell therapy, these “off-the-shelf” products are derived from healthy donor cells, which can be expanded into large master cell banks and used to create many doses for many patients. While this approach promises greater scalability and lower costs, it introduces new manufacturing challenges, such as ensuring batch-to-batch consistency from different donors and managing potential immunogenicity.12

For both modalities, leading CDMOs are moving towards closed, automated manufacturing systems. These technologies are critical for reducing the risk of contamination, minimizing human error, and ensuring the process is reproducible and scalable—a key requirement for late-stage clinical trials and commercialization.15

Core Capability 3: A Robust and Integrated Supply Chain

Successful CGT manufacturing is impossible without a rock-solid supply chain for critical starting materials and a sophisticated logistics network for the final product. A top-tier CDMO provides expertise in two often-underestimated areas:

• Plasmid DNA (pDNA) Manufacturing: High-quality, GMP-grade plasmid DNA is the essential starting material for producing viral vectors and mRNA. A shortage or quality issue with pDNA can bring an entire therapeutic program to a halt. Recognizing this, many leading CGT CDMOs now offer in-house GMP plasmid manufacturing to ensure a reliable, integrated supply for their clients.25
• Specialized Clinical Logistics: As will be discussed further in Service #10, the logistics for CGTs are uniquely demanding. The need for cryogenic (liquid nitrogen) storage and transport, real-time tracking, and the coordination of the “vein-to-vein” journey for autologous therapies is a service in itself. CDMOs that integrate these logistics capabilities offer a seamless, de-risked solution.28

In conclusion, the manufacturing of cell and gene therapies is a frontier of pharmaceutical science. It demands a rare combination of biological expertise, process engineering prowess, stringent quality control, and logistical precision. For developers in this space, a CDMO is not just a vendor; they are the indispensable partner that makes these revolutionary treatments possible.

2. Bioconjugation Excellence: Unlocking the Potential of Antibody-Drug Conjugates (ADCs)

In the relentless fight against cancer, one of the most exciting therapeutic classes to emerge in recent years is the Antibody-Drug Conjugate, or ADC. Often described as “biological missiles” or a “Trojan horse,” ADCs represent a brilliant fusion of two distinct therapeutic worlds: the exquisite targeting specificity of a monoclonal antibody (mAb) and the potent cell-killing power of a cytotoxic small molecule (the “payload”).31 By chemically linking these two components, an ADC can deliver a highly toxic drug directly to a cancer cell, minimizing collateral damage to healthy tissue and dramatically widening the therapeutic window.

The clinical and commercial potential is immense. The global ADC market is on a steep upward trajectory, with forecasts projecting it to reach nearly $20 billion by and potentially over $28 billion by .33 This growth is fueled by a wave of recent approvals and a deep pipeline of candidates targeting a wide range of hematological and solid tumors. However, the very elegance of the ADC concept belies its profound manufacturing complexity.

This dual nature is precisely why specialized CDMOs have become indispensable partners in the ADC space. Successfully producing an ADC is not a single process; it is the flawless integration of three separate, highly demanding cGMP manufacturing workflows. This requires a rare, hybrid organizational structure that has mastered two fundamentally different operational and quality mindsets: the aseptic, controlled world of biologics and the contained, high-hazard environment of potent chemical synthesis.

The Triple Challenge: Integrating Disparate Manufacturing Worlds

The journey of an ADC from concept to vial is a masterclass in multidisciplinary coordination. A CDMO specializing in ADCs must provide world-class capabilities in three distinct areas, often under one integrated quality system :

1. Monoclonal Antibody Production: This is the foundation of the ADC. It involves standard, yet still complex, biologics manufacturing: developing a stable cell line (typically CHO cells), running large-scale fed-batch or perfusion bioreactors, and executing a multi-step downstream purification process to produce the naked mAb at high purity.36
2. Linker-Payload Synthesis: This is the world of high-potency active pharmaceutical ingredient (HPAPI) chemistry. The cytotoxic payloads used in ADCs are often thousands of times more potent than traditional chemotherapy drugs. Their synthesis involves multi-step organic chemistry that must be conducted in specialized high-containment facilities. These facilities are engineered to protect operators from exposure to these toxic compounds, often requiring operations within isolators or “glove boxes” to achieve occupational exposure limits (OELs) measured in nanograms per cubic meter (ng/m3).32 This requires a completely different set of skills, equipment, and safety protocols than biologics manufacturing.
3. Bioconjugation and Purification: This is the critical step where the two worlds meet. The linker-payload is chemically attached to the antibody. This “conjugation” reaction must be precisely controlled to achieve the desired drug-to-antibody ratio (DAR), a critical quality attribute that profoundly impacts the ADC’s efficacy and safety. Following conjugation, the ADC drug substance must be purified to remove any unconjugated antibody, free payload, or other impurities. This is a significant challenge, as the conjugation process can alter the antibody’s properties, making it prone to aggregation and instability.

The challenge for a drug developer is that very few organizations possess world-class expertise and facilities in all three of these areas. A company that excels at mAb production does not automatically have the infrastructure or safety culture for HPAPI handling. This is why the “service you didn’t know you needed” is not just “ADC manufacturing,” but an integrated operational model with a unified quality system that can seamlessly bridge these disparate disciplines. This is the value proposition of leading ADC CDMOs like Lonza, Samsung Biologics, and Abzena, or strategic alliances like Proveo™, which brings together AGC Biologics (for the mAb), Cerbios (for conjugation and payload), and Oncotec (for fill-finish) to create a virtual one-stop-shop.38

The Critical Role of Technology and Analytics

Beyond the core manufacturing steps, two areas of technology are particularly crucial for ADC success:

• Linker Technology: The chemical linker is not merely a tether; it is a sophisticated piece of chemical engineering that determines how and where the payload is released. Cleavable linkers are designed to be broken down by enzymes inside the cancer cell, while non-cleavable linkers release the payload only after the entire antibody is degraded. The choice of linker, and the site on the antibody where it is attached (site-specific vs. stochastic conjugation), are key design features. Some CDMOs, like Abzena with its ThioBridge™ technology, offer proprietary linker platforms that can improve an ADC’s stability and therapeutic index.35
• Analytical Characterization: Analyzing an ADC is a formidable challenge. Unlike a pure mAb, an ADC is a heterogeneous mixture of molecules with different numbers of drugs attached (e.g., DAR of 2, 4, 6, 8). Characterizing this distribution, along with measuring free drug levels, aggregation, and potency, requires a sophisticated suite of analytical tools, as will be discussed in Service #7.39 A CDMO partner must have deep expertise in these ADC-specific analytical methods.

In summary, the development and manufacturing of ADCs is one of the most complex undertakings in the pharmaceutical industry. It requires a partner who is not just a master of one trade, but a seamless integrator of many. For any company looking to enter this promising therapeutic space, a specialized, integrated ADC CDMO is an absolute necessity.

3. Next-Generation Drug Delivery: Lipid Nanoparticle (LNP) and Nanomilling Expertise

A fundamental truth governs our industry: a drug molecule is useless if it cannot reach its target in the body in a sufficient concentration to exert its effect. This concept, known as bioavailability, is one of the greatest hurdles in drug development. An astonishingly high percentage of new small molecule drug candidates—estimates range from 40% to over 70%—are classified as poorly water-soluble, making them difficult for the body to absorb and turning potentially powerful compounds into development dead-ends. At the same time, revolutionary new modalities like mRNA and siRNA are incredibly fragile and cannot survive in the body without a protective delivery vehicle.

Addressing these fundamental delivery and bioavailability challenges is where a CDMO’s expertise in next-generation formulation technologies becomes a true game-changer. These are not mere formulation tweaks; they are enabling platforms that can rescue promising but difficult-to-formulate compounds and make entirely new classes of medicine possible. Two of the most impactful of these services are the manufacturing of Lipid Nanoparticles (LNPs) and the application of Nanomilling. Partnering with a CDMO that has mastered these technologies provides access to strategic assets that can define the success of a development program.

Unlocking Nucleic Acid Therapeutics with Lipid Nanoparticles (LNPs)

The stunningly rapid development and deployment of the COVID-19 mRNA vaccines was a watershed moment for pharmaceutical science. It was also a global showcase for the enabling power of Lipid Nanoparticles. Without LNP technology, there would be no mRNA vaccines.45 These microscopic spheres of fat are the sophisticated delivery vehicles that solve the two biggest problems facing nucleic acid therapeutics:

1. Protection: Naked mRNA or siRNA is rapidly degraded by enzymes in the bloodstream. The LNP acts as a protective shell, shielding its fragile cargo until it reaches the target cell.
2. Delivery: The LNP is engineered to fuse with the cell membrane, allowing it to release the nucleic acid payload into the cell’s cytoplasm where it can be translated into a protein (for mRNA) or interfere with gene expression (for siRNA).

The CDMO service for LNPs is a highly specialized, multi-stage process:

• Formulation Development: An LNP is typically composed of four key lipid components: an ionizable cationic lipid (which binds the negatively charged nucleic acid), a PEGylated lipid (which provides stability and controls particle size), cholesterol (a structural lipid), and a helper phospholipid. Optimizing the type and ratio of these lipids is critical for efficacy and targeting. Some advanced CDMOs, like Fujifilm, even offer proprietary libraries of ionizable lipids to enhance delivery.
• Manufacturing and Scale-Up: The lipids and the nucleic acid are combined in a precise, controlled manner to induce self-assembly into nanoparticles of a specific size (typically <100 nm). This is often accomplished using specialized microfluidic mixing technologies, such as the NanoAssemblr® platform, which allow for reproducible production from small lab-scale batches to large, GMP-grade commercial quantities.48
• Analytical Characterization: A comprehensive suite of analytical tests is required to characterize the final LNP product, including measuring particle size and polydispersity, zeta potential (surface charge), and, most critically, the encapsulation efficiency—the percentage of the nucleic acid that is successfully loaded into the nanoparticles.48

Given the explosion of interest in mRNA and RNAi therapeutics, expertise in LNP formulation and manufacturing is no longer a niche capability; it is a strategic necessity for any CDMO aiming to be a leader in advanced therapies.

Rescuing Poorly Soluble Small Molecules with Nanomilling

While LNPs are solving the delivery challenges of large molecules, nanomilling is a powerful technology for rescuing the vast number of poorly soluble small molecules. The concept is straightforward but technically demanding: if a drug won’t dissolve well because its particles are too large, make the particles smaller—dramatically smaller.44

Nanomilling is a “top-down” particle size reduction technique that uses mechanical force—typically by grinding a drug suspension with tiny ceramic or polymer beads in a specialized mill—to break down drug crystals into nanoparticles, usually in the 100-500 nanometer range. According to the Noyes-Whitney equation of dissolution, reducing the particle size dramatically increases the surface area available for dissolution. This leads to several key benefits:

• Enhanced Dissolution and Bioavailability: Faster dissolution in the gastrointestinal tract leads to better absorption and higher drug exposure in the body.
• Improved Dose Uniformity and Reduced Food Effect: A more consistent absorption profile can make the drug’s effect more predictable.
• Flexible Formulation Options: The resulting nanosuspension can be developed into various dosage forms, including oral tablets/capsules, long-acting injectables, or topical formulations.

The CDMO service for nanomilling involves more than just access to the milling equipment. It requires deep expertise in:

• Pre-formulation and Stabilizer Screening: Preventing the newly created nanoparticles from immediately clumping back together (agglomerating) is critical. This requires selecting the right combination of stabilizing polymers and surfactants.
• Process Development and Scale-Up: Optimizing milling parameters like bead size, agitator speed, and temperature is essential to achieve the target particle size distribution without damaging the drug substance. This process must then be scalable from small development batches to large commercial volumes.
• Aseptic Processing: For injectable nanosuspensions, the entire milling and downstream processing must be conducted under sterile conditions, adding another layer of complexity.

For a company with a promising but poorly soluble compound, partnering with a CDMO with deep nanomilling expertise, such as Ascendia Pharmaceuticals or Pace Analytical, can be the difference between a failed program and a successful product.44 These advanced drug delivery platforms are powerful tools for value creation, turning formulation challenges into commercial opportunities.

4. The 505(b)(2) Fast-Track: Specialized Regulatory Strategy and Execution

In the world of drug development, the traditional path to approval—the 505(b)(1) New Drug Application (NDA)—is a monumental undertaking. It requires a company to generate a complete data package of nonclinical and clinical studies to prove a new drug’s safety and efficacy from scratch. This journey is notoriously long, expensive, and fraught with risk, often taking over a decade and costing upwards of a billion dollars.52 But what if there were a smarter way? A regulatory pathway that allows you to build on the shoulders of giants, leveraging decades of established science to bring an improved product to market faster, with less risk and lower cost?

That pathway exists, and it’s called the 505(b)(2) NDA. This often-underutilized regulatory route is one of the most powerful strategic tools available to drug developers today. However, successfully navigating it requires a unique blend of regulatory savvy, formulation ingenuity, and manufacturing prowess. The “service you didn’t know you needed” is a CDMO that acts not just as a manufacturer, but as a strategic partner in identifying, designing, and executing a winning 505(b)(2) program.

What is the 505(b)(2) Pathway and Why is it a Game-Changer?

The 505(b)(2) pathway, created by the Hatch-Waxman Amendments of , is a hybrid NDA. It requires a full safety and efficacy data package, but it allows the applicant to rely on data not their own—specifically, the FDA’s previous findings of safety and effectiveness for a previously approved drug (known as the “listed drug” or “reference drug”), as well as data from published literature.

This is a game-changer for products that represent an improvement upon an existing drug. Ideal candidates for the 505(b)(2) pathway include 53:

• Drugs with a new dosage form, strength, or route of administration.
• Drugs repurposed for a new indication.
• New fixed-dose combination products.

The strategic advantages are profound. By “bridging” to the existing data of the reference drug, a developer can potentially bypass the need for extensive new nonclinical toxicology studies and large Phase 2 and 3 efficacy trials. This can slash development timelines by years and reduce costs by millions of dollars.53 Furthermore, a successful 505(b)(2) application can be granted its own period of market exclusivity—typically three, five, or even seven years for an orphan drug—creating a new, protected revenue stream.53 The growing appeal of this strategy is evident in the data: in recent years, 505(b)(2) applications have accounted for a majority of all NDA approvals.

The CDMO’s Role: An Integrated Strategy and Execution Partner

A CDMO that truly specializes in the 505(b)(2) pathway provides an integrated suite of services that goes far beyond simple manufacturing. They become a central hub for the entire program:

• Opportunity Identification: The process often begins with identifying a viable 505(b)(2) candidate. This involves a sophisticated analysis of the market landscape, unmet patient needs, and the patent and exclusivity status of existing drugs. This is a prime opportunity to leverage a powerful competitive intelligence platform like DrugPatentWatch, which provides detailed data on patent expiration dates, litigation, and generic entry timelines, helping to pinpoint strategic windows for launching an improved product without infringing on existing IP.55
• Regulatory Strategy: This is perhaps the most critical service. The CDMO’s regulatory experts help design the entire development program and craft the briefing package for the crucial pre-IND meeting with the FDA. The goal is to present a compelling scientific argument that minimizes the number of new studies required to establish the “bridge” to the reference drug.52
• Formulation and CMC: The innovation at the heart of most 505(b)(2) applications is a change in the drug product itself—a new extended-release formulation, a liquid version of a solid pill, or a novel delivery device. The CDMO’s formulation development team (leveraging technologies like those in Service #3) creates this new product and develops the full Chemistry, Manufacturing, and Controls (CMC) data package required for the NDA.57
• Clinical Trial Material Manufacturing and Study Support: The CDMO manufactures the clinical trial material for the necessary bridging studies (e.g., pharmacokinetic or bioequivalence studies) and often works with clinical research partners to help manage these trials.52

Success Stories: How 505(b)(2) Creates Market Leaders

The power of this pathway is best illustrated through real-world examples where strategic formulation changes led to highly successful products:

• Narcan (naloxone) Nasal Spray: The original life-saving opioid overdose reversal agent, naloxone, was an injectable. The 505(b)(2) pathway was used to approve a nasal spray version. By relying on the extensive safety and efficacy data of injectable naloxone, the developer could focus on proving the nasal spray’s usability and bioavailability. The result was a product that was far easier for first responders and laypeople to use in an emergency, addressing a massive public health need and creating a blockbuster product with its own patent protection.
• Bendeka® (bendamustine HCl): The original formulation of this cancer drug, Treanda®, was a powder that required cumbersome reconstitution before IV administration. The 505(b)(2) product, Bendeka®, is a ready-to-use liquid formulation that is safer and more convenient for healthcare providers. This seemingly simple change created a highly successful product by solving a key usability problem for clinicians.

For small and mid-sized companies, the 505(b)(2) pathway is a powerful tool for de-risking development and creating value. It can provide a company with its first revenue-generating asset, which can then be used to fund higher-risk, innovative 505(b)(1) programs. A CDMO with deep, integrated expertise in this pathway is therefore not just a vendor; they are a strategic enabler of their clients’ entire corporate and financial strategy.

5. Human Factors Engineering (HFE): Perfecting the Drug-Device Combination Product

The pharmaceutical industry is increasingly moving beyond the simple pill. The rise of biologics, which are typically injected, and the growing emphasis on patient-centric care have led to an explosion in drug-device combination products. These are products where a drug or biologic is combined with a device for its delivery, such as auto-injectors, pre-filled syringes, inhalers, and transdermal patches.60 For these therapies, the device is not just a container; it is an integral part of the treatment. Its design and usability can be the deciding factor in the product’s safety, effectiveness, and commercial success.

This is where Human Factors Engineering (HFE) comes in. HFE is the scientific discipline of designing products, systems, and environments to be compatible with human capabilities and limitations.63 For combination products, this means ensuring that a patient—who may be elderly, have dexterity issues, or be under stress—can use the device safely and effectively to administer their medication. The FDA and other global regulators now consider a rigorous HFE process to be a mandatory part of development.65 The “service you didn’t know you needed” is a CDMO that doesn’t just assemble devices, but provides integrated HFE expertise as a core part of their offering, transforming a regulatory hurdle into a source of competitive advantage.

The User-Centric Imperative in a Competitive Market

For many biologic drugs, multiple companies may be marketing biosimilar versions of the same active ingredient. In this crowded landscape, what differentiates one product from another in the eyes of patients and physicians? Often, it is the user experience of the delivery device. A device that is less painful, requires fewer steps, provides clearer feedback, and feels more comfortable in the hand will win patient preference and drive market share.67

More critically, poor usability leads directly to use errors, which can have severe consequences. A patient might administer the wrong dose, inject in the wrong location, or fail to hold the device in place for the required duration. These errors can lead to a lack of efficacy or serious adverse events. Therefore, HFE is not just about convenience; it is a fundamental component of patient safety and risk management. A CDMO that provides expert HFE support is not just a manufacturer; they are a user experience (UX) design partner, helping you build a product that patients prefer and, most importantly, use correctly.

The HFE Process: A CDMO-Supported Journey from Concept to Validation

A comprehensive HFE program, as expected by regulators, is an iterative process that runs parallel to the entire product development cycle. A specialized CDMO can provide support at every stage 69:

1. Use-Related Risk Analysis (URRA): This is the foundational step. The HFE team analyzes every step of the device’s use and identifies anything that could go wrong (a “use error”). Each potential error is then assessed for its potential harm to the patient. The tasks associated with the most severe potential harms are designated as “critical tasks” and become the primary focus of the HFE program.63
2. Formative Studies (Iterative Design and Testing): These are early-stage, small-scale usability studies. Representative users (e.g., patients with a specific condition, nurses) are asked to interact with early prototypes of the device and its instructions. Researchers observe their behavior to identify any difficulties or errors. The insights from these studies are then fed back to the engineering team to refine and improve the device design. This cycle of “design, test, refine” is repeated multiple times.70
3. Summative (Validation) Study: This is the final, formal HFE study conducted with the market-ready, final-design product. It is designed to demonstrate to regulators that the device can be used safely and effectively by its intended users, in a realistic use environment, without unacceptable risks. The study must include all critical tasks identified in the URRA. The results of this study form a key part of the regulatory submission package.70

Case Study: Designing an Autoinjector for Patients with Hand Disabilities

The real-world impact of HFE is powerfully illustrated in studies of auto-injectors for patients with rheumatoid arthritis (RA). RA can cause significant pain, swelling, and loss of dexterity in the hands, making the simple act of pushing a button or holding a device challenging.

In a series of HF studies, RA patients, including those with severe hand disabilities, were asked to perform simulated injections with an auto-injector specifically designed for ease of use. The device featured a three-step process designed to be intuitive and require minimal force.67 Through observation and patient feedback, researchers confirmed that even patients with significant dexterity limitations could successfully and consistently use the device. Over 90% of patients found the device acceptable, and the degree of hand disability was not a predictor of failure. This data provided powerful evidence to regulators that the device’s design had successfully mitigated the risks associated with this specific user population, paving the way for its approval.

In an increasingly patient-centric world, the usability of a drug delivery device is paramount. Partnering with a CDMO that possesses deep, integrated HFE capabilities, like Kindeva or PCI Pharma Services, is essential for any company developing a combination product. It is the key to navigating the regulatory landscape, ensuring patient safety, and ultimately, creating a product that wins in the marketplace.69

6. Continuous Manufacturing: The Shift from Batch to Flow for Unmatched Efficiency

For over a century, the pharmaceutical industry has been built on a foundation of batch manufacturing. Much like a baker making individual loaves of bread, this process involves discrete steps: ingredients are loaded into a vessel, a reaction occurs, the product is isolated, and the vessel is cleaned out before the next batch begins. While reliable, this method is inherently inefficient, characterized by long hold times, large equipment footprints, significant waste, and the potential for variability from one batch to the next.74

Now, a transformative technology is poised to upend this long-standing paradigm: Continuous Manufacturing (CM). Already the standard in industries like petrochemicals and food processing, CM represents a shift from discrete batches to an integrated, uninterrupted flow where raw materials are continuously fed into one end of a production line and finished product emerges from the other.75 While the adoption in pharma has been cautious, the momentum is undeniable, driven by strong support from regulatory bodies like the FDA and the pursuit of a more efficient, agile, and resilient manufacturing future.76 For drug developers, accessing this powerful technology without a crippling capital investment is a major challenge, making CDMOs who have invested in CM platforms invaluable strategic partners.

The Compelling Business Case for Continuous Manufacturing

The benefits of shifting from batch to continuous processing are profound and touch every aspect of manufacturing operations. A CDMO offering CM is not just selling a different process; they are selling a fundamentally better way to make medicines, built on three pillars:

• Superior Quality and Consistency: CM systems are integrated with a suite of real-time sensors and analytical tools known as Process Analytical Technology (PAT). These tools continuously monitor Critical Quality Attributes (CQAs) of the product as it’s being made, allowing for immediate adjustments to maintain the process within a state of control. This results in a more consistent, higher-quality product and aligns perfectly with the FDA’s Quality by Design (QbD) initiative.74
• Dramatic Cost Reduction: The efficiency gains of CM translate directly to the bottom line. CM facilities have a much smaller physical footprint (up to 70% smaller) and require less energy to operate. The processes generate less waste and require fewer manual interventions. Studies have estimated that for a high-volume drug, CM can reduce capital expenditures by 20-76% and overall manufacturing costs by 9-40% compared to a traditional batch facility.
• Enhanced Speed and Agility: In a batch process, scaling up from a small clinical reactor to a large commercial one is a major, time-consuming project involving extensive validation. In a CM system, scaling up often means simply running the same compact equipment for a longer period. This drastically shortens development timelines and makes the supply chain more flexible and responsive to changes in market demand.74

Implementation Challenges and the CDMO Advantage

If CM is so advantageous, why hasn’t the entire industry switched over? The barriers to entry are significant. Implementing a CM line requires a massive upfront capital investment in new equipment, sophisticated process control systems, and specialized expertise in areas like process modeling and PAT. For most biopharma companies, particularly smaller ones, this investment is simply prohibitive.74

This is where the strategic value of a CM-capable CDMO becomes clear. By building multi-product CM platforms, these forward-thinking CDMOs allow drug developers to reap the benefits of this advanced technology without bearing the full capital burden. They effectively democratize access to the future of pharmaceutical manufacturing. Companies like WuXi Biologics and SK Biotek are making significant investments in CM-ready facilities, signaling a clear industry trend.

This shift also has profound implications for the global supply chain. The COVID-19 pandemic starkly revealed the vulnerabilities of long, complex supply chains, leading to a strong push for “reshoring” or bringing manufacturing back to domestic soil. The high operational costs of traditional batch manufacturing in Western countries have historically been a major obstacle to this. However, CM’s high degree of automation and lower operating costs fundamentally change this economic equation, making domestic manufacturing competitive again. FDA officials have explicitly championed advanced manufacturing as a key to enhancing supply chain resiliency and national health security. Therefore, a CDMO offering CM is not just providing an efficient process; they are offering a secure, resilient, and often domestic, supply chain—a strategic advantage that transcends a simple cost-per-kilogram comparison.

While CM has been most widely adopted for high-volume small molecule oral solid dosage forms, its application is expanding. Hybrid and fully-connected continuous bioprocessing systems, which link upstream perfusion bioreactors directly to downstream purification steps, are now being implemented for monoclonal antibodies and other biologics, promising to bring the same efficiency revolution to the large-molecule world.75 As this technology matures, partnering with a CDMO at the forefront of the CM wave will be a key differentiator for innovative pharmaceutical companies.

7. Advanced Analytical Characterization: Seeing Your Biologic with Unprecedented Clarity

In the world of small molecule drugs, a product can often be defined by a simple, elegant chemical structure. Its identity, purity, and strength can be confirmed with a relatively standard set of analytical tests. For biologics, however, the reality is infinitely more complex. A monoclonal antibody, a therapeutic protein, or a viral vector is not a single, uniform entity. It is a large, intricate macromolecule produced by living cells, resulting in a heterogeneous mixture of variants with subtle but critical differences in structure and function.82

This complexity is the origin of the foundational principle of biologics development: “the process is the product”. A minor change in the manufacturing process can lead to a significant change in the final product, potentially impacting its efficacy or safety. Consequently, simply performing standard quality control (QC) release testing is not enough. To truly understand, control, and de-risk the development of a biologic, a much deeper level of analysis is required. The “service you didn’t know you needed” is a CDMO that provides a suite of advanced analytical characterization services, using an arsenal of orthogonal, high-resolution techniques to create a detailed molecular “fingerprint” of your product. This service is the ultimate insurance policy against late-stage failure and post-approval supply disruptions.

Why Deep Characterization is Non-Negotiable for Biologics

A biologic’s function is dictated by its complex three-dimensional structure and its post-translational modifications (PTMs)—chemical alterations made to the protein after it is synthesized. One of the most critical PTMs is glycosylation, the pattern of sugar molecules attached to the protein. This “glycan profile” can profoundly influence the drug’s stability, half-life, and immunogenicity.82 Other variants, such as aggregates (clumps of protein) or fragments, can reduce potency or trigger dangerous immune responses.

Regulators at the FDA and EMA demand a thorough understanding and control of these Critical Quality Attributes (CQAs).85 A company must be able to demonstrate not only that each batch meets its release specifications, but also that the manufacturing process is consistent and that the product is well-characterized. This is where an advanced analytical toolbox becomes indispensable.

The Advanced Analytical Toolbox: Beyond Basic QC

A CDMO with leading analytical capabilities offers a multi-pronged approach to characterization, using a battery of orthogonal (different and complementary) methods to build a complete picture of the molecule 87:

• Mass Spectrometry (MS): This is the cornerstone of modern protein characterization. High-resolution mass spectrometry can be used for:

• Intact Mass Analysis: To confirm the overall molecular weight and identify the major glycoforms present on the molecule.
• Peptide Mapping: The protein is digested into smaller peptides, which are then analyzed by LC-MS. This powerful technique can confirm 100% of the amino acid sequence and pinpoint the exact location of PTMs like deamidation or oxidation.82
• Glycan Analysis: The glycans are cleaved from the protein and analyzed separately to provide a detailed profile of the different sugar structures present.
• Advanced Separations: A variety of chromatography and electrophoresis techniques are used to separate and quantify different product variants based on their physical properties:

• Size-Exclusion Chromatography (SEC): Separates molecules by size to quantify aggregates and fragments.
• Ion-Exchange Chromatography (IEX): Separates molecules by charge to detect charge variants caused by modifications like deamidation.
• Capillary Isoelectric Focusing (cIEF): Provides even higher resolution separation of charge variants.
• Biophysical and Potency Assays: These methods assess the drug’s structure and, most importantly, its function:

• Biophysical Techniques: Methods like Circular Dichroism (CD) are used to analyze the protein’s higher-order (secondary and tertiary) structure, ensuring it is properly folded.
• Binding and Potency Assays: These are the ultimate measure of a drug’s effectiveness. ELISA-based binding assays confirm the drug binds to its target, while cell-based potency assays measure its actual biological effect (e.g., its ability to kill cancer cells). These assays are a critical component of any regulatory submission.84

Strategic Applications: The Insurance Policy for Your Program

This powerful analytical toolbox is not just used for a one-time characterization study. It is a strategic asset applied throughout the product lifecycle:

• Process Development and Troubleshooting: These tools provide the real-time insights needed to optimize the manufacturing process and to quickly diagnose the root cause of any batch failures or unexpected results.
• Comparability Studies: It is almost certain that a drug’s manufacturing process will change during its lifecycle (e.g., scaling up for commercial launch, moving to a new facility). A company must prove to regulators that the product made by the new process is “highly similar” to the product made by the old process. This requires a comprehensive, side-by-side analytical comparability exercise, which is impossible without a deep baseline characterization of the original product.82
• Biosimilar Development: For a biosimilar, the entire development program is built on demonstrating a high degree of analytical similarity to the reference innovator product. An advanced characterization package is the foundation of the entire submission.

In essence, investing in a partnership with a CDMO that offers world-class analytical services like Pharmaron or FUJIFILM Diosynth Biotechnologies is a critical risk mitigation strategy.84 It provides the deep product and process understanding required to navigate development, satisfy regulators, and ensure a consistent and reliable supply of medicine to patients for years to come.

8. Pharmaceutical Lifecycle Management: Maximizing Your Asset’s Value Post-Approval

For many emerging biopharma companies, the singular, all-consuming goal is achieving that first regulatory approval. It is the moment of validation, the culmination of years of research and millions of dollars of investment. However, from a strategic business perspective, the initial launch is not the finish line; it is the starting line. The true, long-term value of a pharmaceutical asset is realized in the years and decades following its approval. This is the domain of Pharmaceutical Lifecycle Management (PLM)—a proactive, strategic approach to maximizing a product’s commercial value and extending its competitive lifespan.

While the drug sponsor ultimately owns the commercial strategy, a forward-thinking CDMO is a crucial partner in its execution. The “service you didn’t know you needed” is a CDMO that moves beyond a transactional, project-based mindset to become a long-term steward of your most valuable assets. They don’t just manufacture your launch product; they partner with you to develop the next-generation versions and manufacturing processes that will keep your franchise thriving for years to come.

Beyond the Launch: The Long Game of Product Value

The moment a new drug is launched, the clock starts ticking. Patent cliffs, the emergence of generic or biosimilar competitors, and evolving standards of care all threaten to erode market share over time. A robust PLM strategy is designed to counteract these forces by continuously innovating and improving the product. A strategic CDMO is the engine that powers this innovation, offering specific services to support key PLM tactics 72:

• Next-Generation Formulations: This is one of the most powerful PLM strategies. By developing an improved version of the original product, a company can offer new benefits to patients and physicians, and, critically, secure new patents that extend the product’s protected life. A CDMO partner is essential for this, leveraging their formulation expertise to create:

• More Convenient Dosing: Developing a once-daily, extended-release tablet to replace a product that had to be taken three times a day.
• Improved Delivery Systems: Transitioning an infused biologic to a subcutaneous injection in a user-friendly auto-injector (leveraging Service #5, Human Factors Engineering).
• Pediatric or Geriatric Formulations: Creating a liquid or orally disintegrating tablet version for patients who have difficulty swallowing pills.
  Many of these line extensions can be developed via the streamlined 505(b)(2) pathway (Service #4), making them a highly efficient way to create new value.

• Cost of Goods (COGS) Reduction: As a product matures and faces generic competition, price becomes a key competitive factor. A proactive CDMO will work with the sponsor post-approval to optimize the manufacturing process, improve yields, and drive down the cost of goods. This might involve implementing more efficient technologies like Continuous Manufacturing (Service #6) or applying the principles of Green Chemistry (Service #9). This ensures the branded product can remain competitive even in a crowded market.
• Post-Approval Regulatory Support: Any change to a product or its manufacturing process after approval—whether it’s a new formulation, a new manufacturing site, or a process optimization—requires a formal submission to regulatory authorities. This CMC “post-approval change” process can be complex, especially for biologics.16 A CDMO with a strong regulatory affairs team is essential for managing these submissions efficiently and ensuring an uninterrupted supply of the product.72

Building a Defensive Moat with Strategic Intelligence

An effective PLM strategy is not executed in a vacuum; it must be informed by a deep understanding of the competitive and intellectual property landscape. This is where the strategic use of business intelligence tools becomes critical. By using a platform like DrugPatentWatch, a company and its CDMO partner can monitor the patent expiration dates for their own product and for competitors. This intelligence allows them to strategically time the development and launch of a next-generation product to preempt generic entry and maintain market leadership. For example, knowing that the core patent for your blockbuster drug expires in five years gives you a clear timeline for developing and launching an improved, re-patented version to protect the franchise.

This long-term, strategic approach fundamentally transforms the relationship between a drug developer and its CDMO. The partnership evolves from a series of discrete, transactional projects into a continuous, deeply embedded collaboration focused on the multi-decade success of a key corporate asset. The ideal CDMO partner is one who, from the very first meeting, is already thinking about your product’s lifecycle in five, ten, and fifteen years. They should come to the table with a proactive PLM roadmap, demonstrating that they are thinking not just as a contractor, but as a true partner invested in the long-term success of your medicine.

9. Sustainable Manufacturing & Green Chemistry: Building a Resilient and Responsible Supply Chain

For many years, sustainability in the pharmaceutical industry was often viewed as a “soft” topic—a matter of corporate social responsibility, good for public relations, but secondary to the hard realities of drug development and manufacturing. That view is now dangerously outdated. Today, a robust commitment to sustainable manufacturing and the principles of Green Chemistry is rapidly becoming a non-negotiable business imperative. Driven by a confluence of regulatory pressure, investor demands, and a fundamental shift in supply chain strategy, sustainability is no longer an optional extra; it is a core component of operational excellence and long-term profitability.94

The “service you didn’t know you needed” is a CDMO that has moved beyond “greenwashing” and has deeply embedded the principles of sustainability and green chemistry into its core process development philosophy. This partner understands that the greenest process is almost always the most efficient, robust, and cost-effective process in the long run.

The company is the world’s best Drug Substance CDMO Services supplier. We are your one-stop shop for all needs. Our staff are highly-specialized and will help you find the product you need.

The New Mandate: Why Sustainability is No Longer Optional

Several powerful forces are compelling the industry to prioritize sustainability:

• Regulatory and Customer Pressure: Regulatory bodies are increasingly scrutinizing the environmental impact of manufacturing processes. Furthermore, large pharmaceutical companies, in response to their own ESG (Environmental, Social, and Governance) goals, are now cascading these requirements down their supply chains. A recent survey revealed that 60% of pharmaceutical executives expect to require their CDMO partners to implement and report on sustainability metrics as part of their contracts within the next two years.
• Investor Demands: The investment community is increasingly using ESG criteria to evaluate companies. A poor sustainability track record can be a significant red flag for investors, impacting a company’s valuation and access to capital.
• Operational Efficiency: At its core, sustainability is about efficiency—using fewer resources, creating less waste, and consuming less energy. These are the same goals that drive operational excellence and cost reduction.

The pharmaceutical industry has a significant environmental footprint, with carbon emissions estimated to be up to 55% higher than the automotive sector. Manufacturing operations are a major contributor to this, making the CDMO’s role in driving sustainable practices absolutely critical.

The Green Chemistry Playbook: Smarter Science for a Cleaner Process

Green Chemistry provides a powerful framework of 12 principles for designing chemical processes that are inherently safer and more environmentally benign.100 A forward-thinking CDMO applies these principles not as an afterthought, but as a core part of process development. Key applications in pharmaceutical manufacturing include:

• Waste Prevention: This is the first and most important principle. In pharma, waste is often measured by Process Mass Intensity (PMI), which is the total mass of all materials (solvents, reagents, water) used to produce 1 kg of API. For some processes, the PMI can be over 100. Green chemistry focuses on designing more efficient reactions that generate less waste from the start. From a business perspective, this is simple: waste represents raw materials that were purchased but not converted into valuable product. Reducing waste directly reduces costs.
• Safer Solvents and Reagents: Traditional organic synthesis often relies on large volumes of toxic and flammable solvents. Green chemistry seeks to replace these with safer alternatives, such as water, or to design processes that use less solvent altogether. Another powerful technique is biocatalysis, which uses enzymes to perform chemical reactions with high specificity under mild, water-based conditions, often replacing hazardous reagents and eliminating toxic waste streams.94
• Energy Efficiency: Many chemical reactions require extreme heating or cooling, consuming vast amounts of energy. Green chemistry promotes the use of catalysts (including enzymes) and advanced technologies like Continuous Manufacturing (Service #6) that allow reactions to be run at ambient temperature and pressure, significantly reducing a facility’s energy consumption and carbon footprint.94

Beyond the Molecule: Sustainable Operations in Practice

A true commitment to sustainability extends beyond the chemistry lab to encompass all of a CDMO’s operations. Leading CDMOs are implementing a wide range of initiatives to reduce their environmental impact:

• Renewable Energy: Installing on-site solar panels (photovoltaic systems) to power their facilities.
• Water and Waste Management: Implementing advanced systems to treat and recycle industrial wastewater, and pursuing “zero-waste-to-landfill” goals.96
• Sustainable Logistics and Packaging: Optimizing supply chains to reduce transport distances and emissions, and shifting from single-use, disposable shipping containers to reusable, temperature-controlled shippers, which can prevent millions of pounds of waste from ending up in landfills.

To be credible, these efforts must be measurable and transparent. CDMOs are increasingly using third-party assessors like EcoVadis to benchmark their performance and are setting science-based targets to track their progress toward goals like net-zero emissions.95 Partnering with a CDMO that has a demonstrable and certified commitment to sustainability is no longer just good for the planet; it is a smart, strategic decision that builds a more resilient, efficient, and responsible supply chain for the future.

10. Integrated Clinical Trial Logistics: De-Risking the Journey from Clinic to Patient

The final journey of an investigational drug—from the pristine, controlled environment of a GMP manufacturing suite to a clinical trial site, and ultimately, to a patient—is one of the most perilous and underappreciated stages of drug development. For simple, room-temperature stable small molecules, this process can be relatively straightforward. But for today’s most innovative and valuable therapies—temperature-sensitive biologics and irreplaceable, patient-specific cell therapies—the clinical supply chain is a high-wire act where a single misstep can lead to the loss of a multi-million dollar batch of drug product and, more tragically, a patient missing a critical dose.29

Traditionally, logistics has been viewed as a separate function, often outsourced to a third-party logistics (3PL) provider distinct from the manufacturer. However, for complex therapies, this siloed approach creates unacceptable risks. The “service you didn’t know you needed” is an integrated clinical trial logistics capability offered by your CDMO partner. This service recognizes a fundamental truth: for advanced therapies, the supply chain is part of the therapy itself. A failure in logistics is a failure of the drug.

The High-Stakes World of the Modern Clinical Supply Chain

Managing the supply for a global, multi-center clinical trial for a complex therapy is a formidable challenge, fraught with potential pitfalls 103:

• The Unbreakable Cold Chain: Many biologics and all cell and gene therapies are temperature-sensitive and must be maintained within a strict temperature range (e.g., 2-8°C for refrigerated products, or below -150°C in liquid nitrogen for cryopreserved cells) throughout their journey. Any deviation, or “temperature excursion,” can render the product unusable, compromising its integrity and patient safety.102
• Complex Global Regulations: Each country has its own unique and often complex regulations for importing and exporting clinical trial materials. Navigating customs, permits, and labeling requirements for dozens of countries simultaneously is a major logistical hurdle.
• Forecasting and Flexibility: Patient recruitment in clinical trials is notoriously unpredictable. A CDMO must be able to manage the supply of the investigational medicinal product (IMP) flexibly, adapting to slower-than-expected enrollment at some sites and faster-than-expected enrollment at others, all while minimizing waste of the incredibly expensive drug product.102
• The “Vein-to-Vein” Challenge: For autologous cell therapies, the supply chain is a closed loop of unparalleled complexity. It begins with the collection of a patient’s cells at a clinical site, requires cryopreserved shipment to the manufacturing facility, precise scheduling of the manufacturing slot, and then the return shipment of the final, life-saving therapy back to that specific patient for infusion—all within a very tight timeframe.29

The Integrated CDMO Advantage: A Single Chain of Custody

When a single CDMO partner manages both the manufacturing and the logistics, it creates a seamless, integrated system that dramatically reduces risk and improves efficiency 106:

• Unified Quality and Data Systems: The hand-off between manufacturing and distribution is a major vulnerability. An integrated CDMO maintains a single, unbroken chain of custody and a unified data management system. This ensures that all documentation—from batch records to temperature logs to shipping manifests—is seamlessly connected, which is critical for the final Qualified Person (QP) release of the drug product.
• Streamlined Operations: Integrating manufacturing with packaging, labeling, and distribution eliminates hand-off delays, simplifies project management, and allows for greater agility. For example, a CDMO can use a “just-in-time” labeling strategy, where IMPs are stored as unlabeled “bright stock” and then labeled for specific countries or protocols only as needed, reducing waste and increasing flexibility.
• Specialized Expertise: A CDMO that specializes in a particular therapy type (like cell therapy) will have developed deep, hard-won expertise in its unique logistical requirements. They understand the best shipping containers, the most reliable couriers, and the specific customs requirements for their products.

Case Study: The “Case Manager” for Cell Therapies

The ultimate expression of this integrated service is the “Case Manager” model offered by CDMOs like Catalent for autologous cell therapies. For each patient enrolled in a trial, a dedicated case manager is assigned. This individual acts as a single point of contact, orchestrating every single step of the vein-to-vein journey. They coordinate with the clinical site to schedule the patient’s cell collection (apheresis), book the corresponding manufacturing slot at the CDMO facility, arrange for the specialized cryogenic courier to transport the cells, monitor the shipment in real-time, and then manage the entire process in reverse to deliver the finished therapy back to the hospital for infusion.

This high-touch, white-glove service is the epitome of an integrated logistics solution. It treats the supply chain with the same GMP-level rigor as the manufacturing process itself, because for these therapies, they are one and the same. For any company developing a high-value, sensitive, or personalized therapy, ensuring their CDMO partner has this deep, integrated logistics capability is not just a convenience; it is an absolute prerequisite for success.

Weaving the Threads: Integrating Advanced Services for a Competitive Edge

We have explored ten distinct, high-impact services that are redefining the strategic value of a CDMO partnership. While each service offers a powerful advantage on its own, their true potential is unlocked when they are strategically combined and integrated into a cohesive development program. A savvy biopharma company doesn’t just select a CDMO for a single task; it chooses a partner with a constellation of capabilities that can be woven together to create a formidable and sustainable competitive advantage.

This integrated approach allows a company to move faster, de-risk its pipeline more effectively, and build a multi-layered intellectual property estate that is far more durable than a single patent. To illustrate this synergy, let’s consider a hypothetical case study of “BioNova Therapeutics,” a small, virtual biotech with a promising idea and a lean team.

The Synergy of Specialization: A BioNova Therapeutics Case Study

BioNova’s mission is to develop a next-generation therapy for a rare form of solid tumor that overexpresses a specific cell surface antigen. Their strategy is to create a highly potent and targeted Antibody-Drug Conjugate (ADC). Here is how they could leverage an integrated CDMO partnership to execute this plan:

1. Opportunity Analysis & Strategic Planning: Before synthesizing a single molecule, BioNova’s leadership team uses a competitive intelligence platform like DrugPatentWatch. Their analysis reveals that several first-generation monoclonal antibodies targeting their antigen of interest are nearing patent expiry. This presents a perfect opportunity: they can develop a biobetter mAb and conjugate it to a novel, highly potent payload, creating a new therapeutic with a clear path to market.56 The data from
   DrugPatentWatch helps them design their molecule and patent strategy to avoid infringing on existing IP while creating a strong, defensible position for their new ADC.
2. Integrated Partner Selection: Recognizing the immense complexity of their project, BioNova decides against using separate vendors for the antibody, payload, and conjugation. They seek a single, integrated CDMO partner that excels in Bioconjugation (Service #2). Their due diligence focuses on partners who also have world-class capabilities in Advanced Analytical Characterization (Service #7), as they know that thoroughly understanding the heterogeneous nature of their ADC will be critical for regulatory success. Furthermore, they select a partner with a demonstrated commitment to Sustainable Manufacturing & Green Chemistry (Service #9), which not only aligns with their corporate values but also offers a more efficient and cost-effective synthesis route for their complex payload.
3. Accelerated and De-Risked Execution: The chosen CDMO partner gets to work. Because the ADC is for a rare (orphan) disease, the CDMO’s regulatory team helps BioNova prepare the package for an Orphan Drug Designation. They also provide strategic guidance on how to best leverage expedited regulatory pathways, a service closely related to the expertise required for the 505(b)(2) Fast-Track (Service #4). As the program moves into the clinic, the high value and temperature sensitivity of the ADC make logistics a major concern. Fortunately, their partner offers Integrated Clinical Trial Logistics (Service #10), managing the entire cold chain from the manufacturing suite to the clinical site, ensuring no doses are lost.
4. Proactive Lifecycle Management: From the very beginning of the partnership, the conversation is not just about the first clinical trial, but about the long-term future of the asset. The CDMO’s Pharmaceutical Lifecycle Management (Service #8) team works with BioNova to map out a multi-year plan. They are already exploring a “version 2.0” of the product: a pre-filled syringe for subcutaneous administration that would be more convenient for patients than the initial IV infusion. This plan immediately brings the CDMO’s expertise in Human Factors Engineering (Service #5) into play, as they begin early-stage user studies to design a patient-centric device that will provide a key market advantage in the future.

In this scenario, BioNova, despite being a small company, is able to execute a highly complex, multi-faceted development program that would be impossible without its integrated CDMO partner. By strategically weaving together these advanced services, they have accelerated their timeline, mitigated scientific and regulatory risk, and built a long-term commercial strategy to maximize the value of their innovative therapy.

Identifying Your Partner: Leading CDMOs by Specialized Capability

Selecting the right partner is paramount. The CDMO landscape is vast and diverse, with different organizations excelling in different areas. The table below provides a starting point for identifying potential partners, highlighting some of the industry’s leading players and their noted areas of specialized expertise. This is not an exhaustive list, but rather a representative sample to guide your due diligence process.

Table 2: Leading CDMOs by Specialized Capability

The Future of Outsourcing: What to Expect from Your CDMO Partner in and Beyond

The pharmaceutical outsourcing landscape is not static; it is a dynamic ecosystem in a constant state of evolution. The trends we see today are laying the groundwork for the CDMO of the next decade. As we look toward , the role of the CDMO will become even more deeply integrated, technologically advanced, and strategically indispensable. The ten services detailed in this report are not the endpoint, but rather the foundation upon which the next generation of outsourcing partnerships will be built. Companies that anticipate these future shifts and align themselves with forward-thinking CDMOs will be best positioned for long-term success.

Key Trends on the Horizon

Our analysis of the market points to several key trends that will define the CDMO industry in the coming years:

• Deepening Consolidation and Strategic Specialization: The wave of mergers and acquisitions in the CDMO space is far from over. The industry will continue to consolidate, with the top five players expected to control around 40% of the market by , up from just 15% in . This will result in the emergence of true “players at scale” who can offer a vast array of integrated services across multiple modalities and geographies. Simultaneously, this consolidation will create opportunities for smaller, highly specialized “complementor” CDMOs to thrive by offering deep, best-in-class expertise in niche areas like a specific viral vector serotype or a novel bioconjugation chemistry.
• The Rise of “Pharma 4.0”: Digitalization and AI: The integration of digital technologies will accelerate dramatically. Artificial intelligence (AI) and machine learning will move from the realm of pilot projects to standard operating procedure. We will see AI-driven platforms used for predictive modeling in process development, optimizing manufacturing parameters in real-time, and creating more resilient and transparent supply chains.13 The “digital twin”—a virtual model of a physical manufacturing process—will become a common tool for optimization and troubleshooting.
• Manufacturing for Personalized Medicine: The ultimate frontier of medicine is the “N-of-1” therapy, a treatment designed for a single individual. As these and other personalized medicines (like neoantigen cancer vaccines) move toward the clinic, they will demand a revolution in manufacturing. The CDMO of the future will need to develop highly flexible, automated, and decentralized manufacturing platforms capable of producing these small, bespoke batches efficiently and cost-effectively.
• Sustainability as a Prerequisite for Partnership: The focus on ESG will only intensify. By , sustainability performance will no longer be a secondary consideration; it will be a primary criterion for CDMO selection, on par with quality and cost. CDMOs will be expected to have transparent, audited data on their carbon footprint, water usage, and waste reduction efforts. A commitment to green chemistry and a circular economy will be table stakes for doing business.60
• From Track-and-Trace to Supply Chain Intelligence: The regulatory requirements for serialization and product tracking, such as the Drug Supply Chain Security Act (DSCSA), are creating a massive new stream of data. Forward-thinking CDMOs will leverage this data to offer a new service: real-time supply chain intelligence. By connecting serialization data with inventory levels and distribution channels, they can provide their clients with unprecedented visibility, improving forecasting, preventing stockouts, and enhancing operational intelligence.

The CDMO of will be a technology-driven, data-rich, and deeply integrated partner. They will be judged not just on their ability to manufacture a product, but on their ability to contribute to the entire value chain—from innovative process design to sustainable operations and intelligent supply chain management. The partnerships of the future will be built on a foundation of shared data, aligned strategic goals, and a mutual commitment to bringing the next generation of medicines to patients faster, safer, and more efficiently than ever before.

Conclusion: Your Blueprint for Strategic Outsourcing Success

The journey of a new medicine from a promising molecule to a life-changing therapy is one of the most challenging endeavors in modern science and business. The traditional model of pharmaceutical development, reliant on massive internal infrastructure and tactical outsourcing, is no longer sufficient to navigate this complex landscape. The data is unequivocal: the industry has embraced a new paradigm, one where the Contract Development and Manufacturing Organization is not a peripheral vendor, but a central, strategic partner in the creation of value.

This report has sought to illuminate the capabilities that define this new generation of CDMO partners. We have moved beyond the standard menu of services to uncover the ten high-impact, often underappreciated, capabilities that provide a true competitive advantage. From mastering the immense complexity of cell and gene therapies to leveraging the streamlined 505(b)(2) regulatory pathway; from perfecting the user experience of a combination product through Human Factors Engineering to revolutionizing efficiency with Continuous Manufacturing; these services represent the cutting edge of pharmaceutical development.

They are united by a common thread: they transform the CDMO relationship from a transactional one, focused on cost and capacity, to a strategic one, focused on innovation, speed, and risk mitigation. Choosing a CDMO is no longer a simple procurement decision; it is one of the most critical strategic choices a biopharma company will make. It is a decision that will profoundly impact a program’s timeline, its probability of success, its intellectual property portfolio, and its ultimate commercial value.

The blueprint for success in this new era is clear. It requires leaders to look beyond the basics and to seek out partners who are not just “hands” but “brains”—partners who bring deep scientific expertise, advanced technological platforms, and a proactive, problem-solving mindset to the table. By understanding and strategically leveraging the powerful services detailed in this report, biopharmaceutical companies of all sizes can de-risk their pipelines, accelerate their journeys, and more effectively fulfill their ultimate mission: bringing innovative, life-changing medicines to the patients who need them.

Key Takeaways

• The CDMO is a Strategic Partner, Not a Vendor: The modern CDMO has evolved from a simple manufacturing provider to an integrated partner essential for innovation, speed, and risk mitigation. The global market’s projected growth to $465 billion by underscores this fundamental industry shift.
• Advanced Therapies Demand Specialized Expertise: The manufacturing of Cell & Gene Therapies and Antibody-Drug Conjugates is extraordinarily complex, requiring a rare blend of expertise in biologics, high-potency chemistry, and specialized logistics. For these modalities, a specialized CDMO partnership is non-negotiable.
• Drug Delivery and Formulation Create New Value: Services like LNP formulation and nanomilling are not just problem-solvers for difficult compounds; they are enabling technologies that make new therapeutic classes (like mRNA) possible and can rescue promising but poorly soluble molecules from failure.
• Regulatory Strategy Can Be Outsourced: The 505(b)(2) pathway is a powerful business strategy for creating new, patent-protected products with less risk and cost. A CDMO with integrated regulatory and formulation expertise can be a key partner in executing this “fast-track” approach.
• For Combination Products, User Experience is Key: Human Factors Engineering (HFE) is a mandatory regulatory requirement and a critical driver of commercial success for drug-device products. A CDMO with HFE expertise helps design safer, more effective, and patient-preferred therapies.
• Continuous Manufacturing is the Future: While still emerging, Continuous Manufacturing offers transformative benefits in quality, cost, and supply chain resilience. CDMOs are leading the adoption of this technology, making it accessible to companies without the massive capital investment.
• Deep Analytical Characterization is Your Program’s Insurance Policy: For complex biologics, a comprehensive analytical package using advanced, orthogonal methods is essential for de-risking development, ensuring regulatory approval, and managing post-approval manufacturing changes.
• Value Extends Beyond Launch: Pharmaceutical Lifecycle Management services, offered by a long-term CDMO partner, can extend a product’s patent life, improve its market position, and maximize its value for years after initial approval.
• Sustainability is a Business Imperative: Green chemistry and sustainable manufacturing practices are no longer optional. They are key drivers of operational efficiency, cost reduction, and are becoming a prerequisite for partnership selection by major pharmaceutical companies and investors.
• Logistics is Part of the Therapy: For high-value, sensitive, and personalized medicines, the clinical supply chain is a critical extension of the manufacturing process. An integrated logistics service from a CDMO is the best way to ensure these precious therapies reach patients safely and on time.

Frequently Asked Questions (FAQ)

1. How should a small, virtual biotech with limited in-house technical staff approach the due diligence process for a highly specialized CDMO?

For a resource-constrained biotech, the due diligence process must be ruthlessly efficient and focused. First, leverage your network—investors, board members, and scientific advisors—for trusted referrals. Second, focus your initial vetting on CDMOs that explicitly specialize in your specific need (e.g., AAV viral vectors, ADCs with a specific linker chemistry). Review their case studies and publications to verify their track record.106 Third, during the evaluation process, be transparent about your internal limitations and frame the relationship as a partnership. Ask probing questions about their project management and communication processes: Who will be your dedicated project manager? How often will you have technical meetings? How do they handle unexpected scientific challenges?106 Finally, consider hiring an independent CMC consultant with deep expertise in your specific area to act as your “owner’s representative” during the technical evaluation and negotiation. This small investment can prevent catastrophic mistakes in partner selection.

2. What are the key contractual terms to look for when engaging a CDMO for an integrated service like 505(b)(2) development or lifecycle management?

For integrated, long-term services, the contract must go beyond a simple fee-for-service scope of work. Key terms to scrutinize include: Intellectual Property (IP): The agreement must clearly state that the client owns all IP related to their molecule and the specific product developed. However, it should also define the ownership of any new process improvements or platform technologies the CDMO develops during the project. Governance and Project Management: The contract should establish a clear governance structure, including a joint steering committee with defined decision-making authority. It should also specify the frequency and format of progress reports and meetings. Flexibility and Change Orders: Long-term projects inevitably encounter changes. The contract should have a well-defined, fair, and efficient process for managing scope changes and amendments without being overly punitive. Long-Term Supply and Pricing: For lifecycle management, the agreement should include terms for long-term commercial supply, including forecasting mechanisms, capacity reservation, and a framework for future price adjustments based on volume or process improvements. Exit Strategy: While you hope for a long partnership, the contract should include clear terms for technology transfer and exit, outlining the CDMO’s responsibilities in compiling a complete data package should you need to move the project to another facility.

3. With the rise of advanced therapies, is the traditional, chemistry-focused small molecule CDMO becoming obsolete?

Not at all. While advanced therapies are the fastest-growing segment, the small molecule market remains vast and is still growing. The key is that the demands on small molecule CDMOs are evolving. First, many advanced therapies, like ADCs and LNPs, have critical small molecule components (payload-linkers, custom lipids), creating new demand for highly specialized and often high-potency chemical synthesis. Second, there is a strong push for innovation in small molecule delivery and manufacturing through services like nanomilling, the 505(b)(2) pathway, and continuous manufacturing. Therefore, the traditional small molecule CDMO is not becoming obsolete, but it is bifurcating. Those that continue to offer only basic, commodity API synthesis will face intense price pressure, while those that invest in these high-value, specialized services will thrive as critical innovation partners.

4. How can we quantify the ROI of investing more in a premium CDMO with advanced capabilities versus a lower-cost, more basic provider?

Quantifying the ROI requires looking beyond the initial quote and modeling the total cost and value of the program. The calculation should include: Risk Adjustment: A premium CDMO with a proven track record and advanced analytical capabilities may have a higher probability of technical and regulatory success. You can model this by assigning a higher probability of success (e.g., 70% vs. 50%) to the development milestones, which dramatically impacts the risk-adjusted Net Present Value (rNPV) of the project. Speed to Market: A more experienced, integrated CDMO can often shorten timelines. Calculate the commercial value of launching your product 6, 12, or 18 months earlier. The additional revenue captured by an earlier launch can often dwarf the upfront cost difference between CDMOs. Cost of Failure or Delay: Model the cost of a major manufacturing failure, such as a lost batch or a long regulatory delay. A premium partner’s robust quality systems and proactive risk mitigation can be viewed as an insurance policy against these catastrophic costs. A single failed batch of a biologic can cost millions, immediately erasing any savings from a lower-cost provider. Lifecycle Value: A partner that can help you execute a PLM strategy to gain an extra 3-5 years of patent life is creating value that is orders of magnitude greater than their service fees. By building a financial model that incorporates these factors, the higher upfront cost of a premium CDMO often emerges as the far superior long-term investment.

5. What is the single biggest mistake companies make when managing their relationship with a CDMO partner, and how can it be avoided?

The single biggest mistake is treating the CDMO like a transactional vendor rather than a true partner, which manifests as poor communication and a lack of transparency. Companies often “throw the project over the wall” and expect a perfect result with minimal interaction. This almost always leads to misunderstandings, misaligned expectations, and costly delays. The solution is to establish a culture of radical transparency and “overcommunication” from day one. This means: Establishing a Joint Project Team: Create a single, integrated team with members from both the sponsor and the CDMO, led by dedicated project managers on both sides. Frequent and Structured Communication: Implement a regular cadence of meetings (e.g., weekly technical meetings, bi-weekly steering committee meetings) with clear agendas and action items. Sharing the “Why”: Don’t just share the technical protocol; share the strategic context. Explain the clinical development plan, the competitive landscape, and the commercial goals. When the CDMO understands why a certain timeline is critical or why a specific product attribute is important, they can make better, more proactive decisions. A successful CDMO relationship is a human relationship built on trust and open dialogue. Investing in that communication is the single most important factor in ensuring a successful outcome.

References

1. 5 Key Questions to Help You Select a Pharma CDMO Partner, accessed August 3, , https://pharma-tech.com/5-key-questions-to-help-you-select-a-pharma-cdmo-partner/
2. CDMO Services: Top Solutions to Transform Your Pharma Journey, accessed August 3, , https://adragos-pharma.com/cdmo-services-top-solutions-to-transform-your-pharma-journey/
3. Contract manufacturing organization – Wikipedia, accessed August 3, , https://en.wikipedia.org/wiki/Contract_manufacturing_organization
4. What is a CDMO & How Do They Help Pharma Companies? – Medical Packaging Inc, accessed August 3, , https://medpak.com/cdmo-pharma/
5. CDMO in Pharma and Biotech: What is it and why do you need one – PharmaSource, accessed August 3, , https://pharmasource.global/content/cdmo-explained-an-overview-of-contract-development-and-manufacturing-organisations-in-pharma/
6. CROs vs CMOs, and CDMOs: What’s the difference between the three? – Patheon, accessed August 3, , https://www.patheon.com/us/en/insights-resources/blog/cdmo-vs-cmo-vs-cro.html
7. CDMO Market Size, Share & Trends | Growth Analysis [] – Fortune Business Insights, accessed August 3, , https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-
8. What is a CDMO & How Can CDMO Services Benefit Your Pharma Development?, accessed August 3, , https://www.upm-inc.com/what-is-a-cdmo
9. Contract Development & Manufacturing Services – DN Life Science, accessed August 3, , https://dnlifesciences.com/services/contract-development-manufacturing-services
10. Outsourcing’s Evolution in the Pharma Industry – Pharmaceutical Executive, accessed August 3, , https://www.pharmexec.com/view/outsourcing-evolution-pharma-industry
11. CDMOs are becoming emerging technology leaders | EY – US, accessed August 3, , https://www.ey.com/en_us/insights/strategy/how-cdmo-companies-are-leading-innovation-for-pharmaceutical-partners
12. Cell and gene therapy market outlook strong despite technical challenges, accessed August 3, , https://www.clinicaltrialsarena.com/sponsored/cell-and-gene-therapy-market-outlook-strong-despite-technical-challenges/
13. 7 Common Cell and Gene Therapy Manufacturing Challenges (and How To Solve Them), accessed August 3, , https://pharmasource.global/content/expert-insight/7-common-cell-and-gene-therapy-manufacturing-challenges-and-how-to-solve-them/
14. Cell and Gene Therapy CDMO Market Leads 27.94% CAGR by – Towards Healthcare, accessed August 3, , https://www.towardshealthcare.com/insights/cell-and-gene-therapy-cdmo-market-sizing
15. www.towardshealthcare.com, accessed August 3, , https://www.towardshealthcare.com/insights/cell-and-gene-therapy-cdmo-market-sizing#:~:text=The%20global%20cell%20and%20gene,27.94%25%20between%%20and%.
16. Late-Stage Cell Therapy: Key Challenges and the CDMO Advantage | Contract Pharma, accessed August 3, , https://www.contractpharma.com/late-stage-cell-therapy-key-challenges-and-the-cdmo-advantage/
17. Regulatory Knowledge Guide for Biological Products – NIH SEED Office, accessed August 3, , https://seed.nih.gov/sites/default/files/-03/Regulatory-Knowledge-Guide-Biological-Products.pdf
18. Viral vector development and manufacturing services – Patheon, accessed August 3, , https://www.patheon.com/us/en/our-capabilities/advanced-therapies/viral-vector-manufacturing-services.html
19. Viral Vector Manufacturing Services | Gene Therapies – AGC Biologics, accessed August 3, , https://www.agcbio.com/capabilities/viral-vector
20. Viral Vector Manufacturing CDMO | Preclinical to Commercial GMP – Halix B.V., accessed August 3, , https://www.halix.nl/viral-vector-manufacturing/
21. Top 10 Contract Manufacturing Organization and CDMO – AGC Biologics, accessed August 3, , https://www.agcbio.com/biopharma-blog/agc-biologics-was-named-a-top-10-cmo
22. CAR-T Manufacturing Services – Charles River Laboratories, accessed August 3, , https://www.criver.com/products-services/cell-and-gene-therapy-cdmo-solutions/cell-therapy-manufacturing/car-t-cell-manufacturing-services
23. Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility – PubMed Central, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
24. Advanced Therapies, accessed August 3, , https://advancedtherapies.com/
25. Cell Therapy Development and Manufacturing Services | AGC Biologics, accessed August 3, , https://www.agcbio.com/capabilities/cell-therapy
26. Plasmid DNA Manufacturing – Cell and Gene, accessed August 3, , https://www.cellandgene.com/doc/plasmid-dna-manufacturing-
27. Plasmid DNA – Catalent Biologics, accessed August 3, , https://biologics.catalent.com/specialty/plasmid-dna/
28. Plasmid DNA Manufacturing | SK pharmteco, accessed August 3, , https://www.skpharmteco.com/cell-gene-therapy/plasmid-dna-manufacturing/
29. Partnerships in Cell and Gene Therapy Clinical Trials – IQVIA, accessed August 3, , https://www.iqvia.com/blogs//02/partnerships-in-cell-and-gene-therapy-clinical-trials
30. Navigating nuanced CGT clinical trial logistics | Cellgenetherapyreview.com, accessed August 3, , https://www.cellgenetherapyreview.com/-Featured-Articles/-Navigating-nuanced-CGT-clinical-trial-logistics/
31. Catalent Launches Case Management of Cell and Gene Therapies, accessed August 3, , https://clinical.catalent.com/catalent-news/catalent-launches-supply-chain-case-management-for-cell-and-gene-therapies/
32. ADC Antibody Drug Conjugates CDMO Market – PharmaSource, accessed August 3, , https://pharmasource.global/content/antibody-drug-conjugates-adc-contract-manufacturing-market/
33. Interview – Challenges in the Development & Manufacturing of ADCs – GTP Bioways, accessed August 3, , https://www.gtp-bioways.com/biologics/challenges-development-manufacturing-adc/
34. Antibody Drug Conjugates Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed August 3, , https://www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-.html
35. Antibody Drug Conjugates Market Size | Companies – Nova One Advisor, accessed August 3, , https://www.novaoneadvisor.com/report/antibody-drug-conjugates-market
36. Antibody Drug Conjugate Manufacturing | ADC Manufacturing – Abzena, accessed August 3, , https://abzena.com/biologics/bioconjugates-and-adcs/manufacturing/adc-manufacturing/
37. Lonza | A Dedicated CDMO Serving the Healthcare Industry, accessed August 3, , https://www.lonza.com/
38. Navigating the Future of Bioconjugates and ADCs: An Expert Q&A with Iwan Bertholjotti, accessed August 3, , https://www.lonza.com/knowledge-center/smallmolecules/a/strategic-planning-in-adc-development
39. Antibody-Drug Conjugate | New Modalities | Our Services – Samsung Biologics, accessed August 3, , https://samsungbiologics.com/services/adc
40. ADC Manufacturing’s Biggest CMC Challenges And Ways To Approach Them, accessed August 3, , https://www.bioprocessonline.com/doc/adc-manufacturing-s-biggest-cmc-challenges-and-ways-to-approach-them-
41. Leading Biologics, Bioconjugates & ADC CDMO – Abzena, accessed August 3, , https://abzena.com/cdmo/
42. Antibody Drug Conjugates (ADC) Manufacturing & Development Partnership – AGC Biologics, accessed August 3, , https://www.agcbio.com/proveo-partnership-antibody-drug-conjugates
43. A CDMO’s Perspective on Outsourcing Challenges for ADCs–Part 2, accessed August 3, , https://www.pharmtech.com/view/cdmo-perspective-outsourcing-challenges-adcs-part-2
44. Overcoming Development Challenges in Antibody-Drug Conjugates | Biocompare.com, accessed August 3, , https://www.biocompare.com/Editorial-Articles/-Overcoming-Development-Challenges-in-Antibody-Drug-Conjugates/
45. Nanomilling for Enhanced Drug Delivery: Ascendia Pharmaceutical Solutions’ Expertise in Action, accessed August 3, , https://ascendiacdmo.com/newsroom/nanomilling-for-enhanced-drug-delivery-ascendia-pharmaceutical-solutions-expertise-in-action
46. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging – PubMed Central, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
47. Lipid Nanoparticles From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement – ACS Publications, accessed August 3, , https://pubs.acs.org/doi/10./acsnano.1c
48. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines – PMC, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
49. Lipid Nanoparticles – Fujifilm Pharma, accessed August 3, , https://www.fujifilmpharma.com/lipid-nanoparticles/
50. Lipid Nanoparticle (LNP) Formulation Services for mRNA – Vernal Biosciences, accessed August 3, , https://www.vernal.bio/services-and-products/lnp-formulated-mrna/
51. Lipid Nanoparticle CDMO Services – Helix Biotech, accessed August 3, , https://www.helixbiotech.com/services
52. Nanomilling Bead Milling – Pace Analytical, accessed August 3, , https://www.pacelabs.com/life-sciences/cdmo-cro-services/small-molecules/clinical-supplies-manufacturing/nanomilling/
53. 505(b)(2) Pathway | CRO Services | Consulting – Premier Research, accessed August 3, , https://premier-research.com/expertise/505b2-development-pathway/
54. What Is 505(b)(2)? | Premier Consulting, accessed August 3, , https://premierconsulting.com/resources/what-is-505b2/
55. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements – DrugPatentWatch, accessed August 3, , https://www.drugpatentwatch.com/blog/review-of-drugs-approved-via-the-505b2-pathway-uncovering-drug-development-trends-and-regulatory-requirements/
56. Leveraging 505(b)(2) to Innovate Beyond Existing Drug Patents – DrugPatentWatch, accessed August 3, , https://www.drugpatentwatch.com/blog/leveraging-505b2-to-innovate-beyond-existing-drug-patents/
57. DrugPatentWatch | Software Reviews & Alternatives – Crozdesk, accessed August 3, , https://crozdesk.com/software/drugpatentwatch
58. 505(b)(2) Strategy & Consulting | Vici Health Sciences, accessed August 3, , https://vicihealthsciences.com/cmc-regulatory-services/505b2-strategy-and-consulting/
59. Contract Development And Manufacturing Organization Services – LGM Pharma, accessed August 3, , https://lgmpharma.com/cdmo-services/
60. Navigating the 505(b)(2) Pathway: No Two Drugs Are Alike – Premier Research, accessed August 3, , https://premier-research.com/perspectives/navigating-the-505b2-pathway-no-two-drugs-are-alike/
61. Strategic CDMO Growth in a Dynamic Market – PCI Pharma Services, accessed August 3, , https://pci.com/resources/strategic-cdmo-growth-in-a-dynamic-market/
62. Human Factors Engineering and Testing for Combination Products | UL Solutions LATAM, accessed August 3, , https://latam.ul.com/en/news/human-factors-engineering-and-testing-combination-products
63. Device Drug Combination Products – DDCP | Hemoteq / English, accessed August 3, , https://www.hemoteq.com/en/what-we-offer/products-technologies/device-drug-combination-products-ddcp/
64. FDA Issues Human Factors Guidance for Combination Products – Exponent, accessed August 3, , https://www.exponent.com/article/fda-issues-human-factors-guidance-combination-products
65. The Importance of Human Factors Engineering in Combination Product Development, accessed August 3, , https://www.iancollmceachern.com/single-post/the-importance-of-human-factors-engineering-in-combination-product-development
66. Human Factors for Combination Products – AAMI, accessed August 3, , https://www.aami.org/training/training-suites/human-factors/human-factors-for-combination-products
67. Application of Human Factors Engineering Principles for Combination Products: Questions and Answers Guidance for Industry and FDA Staff September , accessed August 3, , https://www.fda.gov/regulatory-information/search-fda-guidance-documents/application-human-factors-engineering-principles-combination-products-questions-and-answers
68. Results of a human factors experiment of the usability and patient acc – Dove Medical Press, accessed August 3, , https://www.dovepress.com/results-of-a-human-factors-experiment-of-the-usability-and-patient-acc-peer-reviewed-fulltext-article-PPA
69. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
70. Optimizing Drug-Device Combination Product Manufacturing – PCI Pharma Services, accessed August 3, , https://pci.com/resources/drug-device-combination-manufacturing/
71. Human factors evaluation of a novel digital medicine system in psychiatry – PMC, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
72. Human Factors Testing and Clinical Research – SOCRA Blog, accessed August 3, , https://www.socra.org/blog/human-factors-testing-and-clinical-research/
73. Post-commercialization – Kindeva CDMO, accessed August 3, , https://www.kindevadd.com/cdmo-services/post-commercialization/
74. CDMO Manufacturing | Pharma Contract Manufacturing – Kindeva Drug Delivery, accessed August 3, , https://www.kindevadd.com/cdmo-services/manufacturing/
75. Continuous manufacturing (flow chemistry) – the future of pharmaceutical manufacturing | Veranova, accessed August 3, , https://veranova.com/expert-insights/continuous-manufacturing-the-future-of-pharmaceutical-manufacturing/
76. A View Into the Promise of Continuous Manufacturing | L.E.K. Consulting, accessed August 3, , https://www.lek.com/insights/hea/eu/ei/view-promise-continuous-manufacturing
77. Exploring Continuous Manufacturing Technology and Applications in the Pharmaceutical Industry | U.S. Pharmacopeia Blog – Quality Matters, accessed August 3, , https://qualitymatters.usp.org/exploring-continuous-manufacturing-technology-and-applications-pharmaceutical-industry
78. FDA Highlights Importance of Advanced Medical Manufacturing to Support Health, accessed August 3, , https://waysandmeans.house.gov//08/04/fda-highlights-importance-of-advanced-medical-manufacturing-to-support-health/
79. Continuous Manufacturing in Pharmaceuticals: Implications for the Generics Market, accessed August 3, , https://drug-dev.com/continuous-manufacturing-continuous-manufacturing-in-pharmaceuticals-implications-for-the-generics-market/
80. Reimagining Continuous Manufacturing for Biologics: Beyond Perfusion to a Fully Connected Process | Contract Pharma, accessed August 3, , https://www.contractpharma.com/reimagining-continuous-manufacturing-for-biologics-beyond-perfusion-to-a-fully-connected-process/
81. A View Into the Promise of Continuous Manufacturing – L.E.K. Consulting, accessed August 3, , https://www.lek.com/sites/default/files/insights/pdf-attachments/continuous-manufacturing.pdf
82. Continuous manufacturing in pharmaceuticals: Economic and policy issues – Bates White, accessed August 3, , https://www.bateswhite.com/media/publication/171_Continuous%20Manufacturing.pdf
83. Mass spectrometry, a tool for the characterisation of monoclonal antibodies – A3P, accessed August 3, , https://www.a3p.org/mass-spectrometry-antibodies/
84. Mass Spectrometry for the Biophysical Characterization of Therapeutic Monoclonal Antibodies – PMC, accessed August 3, , https://pmc.ncbi.nlm.nih.gov/articles/PMC/
85. Advanced Analytical Development and Testing for Biologics – Pharmaron, accessed August 3, , https://www.pharmaron.com/services/biologics-cgt/biologics-cdmo/analytical-services/
86. Analytical Service GMP – FUJIFILM Diosynth Biotechnologies, accessed August 3, , https://fujifilmbiotechnologies.fujifilm.com/capabilities/analytical-service-gmp/
87. Bioanalytical Services, Quality Control of Biologics – Mabion, accessed August 3, , https://www.mabion.eu/analytics/
88. Biologic Analytical Development, accessed August 3, , https://www.pacelabs.com/life-sciences/cdmo-cro-services/biologics/analytical-development/
89. Advanced Bioanalytical Services for Biologics – Ensuring Quality Control in Biopharmaceuticals – Smore Science, accessed August 3, , https://www.smorescience.com/advanced-bioanalytical-services-for-biologics-ensuring-quality-control-in-biopharmaceuticals/
90. Case Studies & Customer Stories – AGC Biologics, accessed August 3, , https://www.agcbio.com/case-studies
91. Commercial Pharmaceutical Manufacturing & Lifecycle Management – SK pharmteco, accessed August 3, , https://www.skpharmteco.com/small-molecule/api-drug-substance-development/commercial-manufacturing-lifecycle-management/
92. Explore Our CDMO Services – Vetter Pharma, accessed August 3, , https://www.vetter-pharma.com/en/services/
93. Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products | FDA, accessed August 3, , https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-changes-approved-application-certain-biological-products
94. Regulatory Support & Dossier Compilation – CDMO Services – Aizant, accessed August 3, , https://www.aizant.com/services/contract-development-manufacturing-organization/regulatory-support-dossier-compilation/
95. Sustainability in pharmaceutical manufacturing: a CDMO’s contribution | BioPharma Dive, accessed August 3, , https://www.biopharmadive.com/spons/sustainability-in-pharmaceutical-manufacturing-a-cdmos-contribution//
96. Evolving with purpose in the CDMO industry – World Finance, accessed August 3, , https://www.worldfinance.com/markets/evolving-with-purpose-in-the-cdmo-industry
97. How can pharma manufacturing align with green initiatives while maintaining efficiency and compliance?, accessed August 3, , https://www.pharmasalmanac.com/articles/how-can-pharma-manufacturing-align-with-green-initiatives-while-maintaining-efficiency-and-compliance
98. The role of CDMOs in creating a more sustainable pharmaceutical supply chain, accessed August 3, , https://pci.com/resources/the-role-of-cdmos-in-creating-a-more-sustainable-pharmaceutical-supply-chain/
99. What Pharma Needs to Know About Green Chemistry – News-Medical.net, accessed August 3, , https://www.news-medical.net/life-sciences/What-Pharma-Needs-to-Know-About-Green-Chemistry.aspx
100. CDMOs Clean Up Act: Environmental Responsibility – PCI Pharma Services, accessed August 3, , https://pci.com/resources/cdmos-clean-up-act-environmental-responsibility/
101. The Role of Green Chemistry in Generic Drug Development: A Sustainable Approach to Medicine – DrugPatentWatch – Transform Data into Market Domination, accessed August 3, , https://www.drugpatentwatch.com/blog/the-role-of-green-chemistry-in-generic-drug-development-a-sustainable-approach-to-medicine/
102. Driving sustainable drug discovery and development using Green Chemistry – AstraZeneca, accessed August 3, , https://www.astrazeneca.com/what-science-can-do/topics/sustainability/sustainable-drug-discovery-using-green-chemistry.html
103. Navigating Clinical Trial Supply Management: Challenges, Trends & Smarter Strategies, accessed August 3, , https://comac-medical.com/navigating-clinical-trial-supply-management-challenges-trends-and-smarter-strategies/
104. Top 5 Challenges in Clinical Trial Supply Chain Operations (and How to Overcome Them), accessed August 3, , https://www.pronavclinical.com/post/top-5-challenges-in-clinical-trial-supply-chain-operations
105. The 3 biggest challenges in the clinical trial supply chain, accessed August 3, , https://lifesciences.n-side.com/blog/3-biggest-challenges-in-clinical-supply-chain
106. Logistics For Cell & Gene Therapy Trials: Specific Needs Demand Special Skills – Cerba Research, accessed August 3, , https://www.cerbaresearch.com/wp-content/uploads//12/Logistics-in-CG-Whitepaper.pdf
107. What is a CDMO and what to look for in a partner – Patheon pharma services, accessed August 3, , https://www.patheon.com/us/en/insights-resources/blog/what-is-a-cdmo.html
108. The importance of a CDMO: Development to commercialization and beyond – PCI Services, accessed August 3, , https://pci.com/resources/contract-development-to-commercialization-and-beyond/
109. DrugPatentWatch Custom Market Surveillance – Iscitech, accessed August 3, , https://www.iscitech.com/drugcustommarket.htm
110. Hung Trinh: Top 10 CDMO ranking based on sales revenue and operation – OncoDaily, accessed August 3, , https://oncodaily.com/blog/
111. Top 10 CDMOs – PharmaBoardroom, accessed August 3, , https://pharmaboardroom.com/articles/top-10-cdmos-/
112. End-to-end Cell & Gene Therapy CDMO Services – Patheon, accessed August 3, , https://www.patheon.com/us/en/our-capabilities/advanced-therapies.html
113. 505(b)(2) Pathway Projects And API Supply Experts – LGM Pharma, accessed August 3, , https://lgmpharma.com/api-sourcing/505b2-pathway/
114. Green Chemistry in CDMO World. Thermo Fisher Scientific’s Approach to Sustainable API Development and Manufacturing – CPHI Online, accessed August 3, , https://www.cphi-online.com/video/green-chemistry-in-cdmo-world-thermo-fisher-scientific-s-approach-to-sustainable-api-development/
115. Pharma Contract Development and Manufacturing Organization (CDMO) Predictions for – Alvarez & Marsal, accessed August 3, , https://www.alvarezandmarsal.com/sites/default/files/-05/Pharma%20Contract%20Development%20and%20Manufacturing%20Organization%20%28CDMO%29%20Predictions%20for%.pdf
116. Five Trends That Will Redefine the CDMO Industry in – The Pharma Navigator, accessed August 3, , https://www.thepharmanavigator.com/news/five-trends-that-will-redefine-the-cdmo-industry-in-
117. The Impact of Serialization & Track-and-Trace Requirements on API Contract Manufacturing, accessed August 3, , https://neunco.com/contract-manufacturing/the-impact-of-serialization-track-and-trace-requirements-on-api-contract-manufacturing/
118. Serialization and Track and Trace Solutions for CMOs and CPOs | OPTEL, accessed August 3, , https://www.optelgroup.com/en/industry/solutions-for-cmos-and-cpos/
119. How to Choose the Right CDMO Partner: Key Factors to Consider – Bachem, accessed August 3, , https://www.bachem.com/articles/blog/how-to-choose-the-right-cdmo-partner-key-factors-to-consider/

Copyright © DrugPatentWatch. Originally published at

As the number of therapeutic molecules in development has more than doubled – from about 6,000 to in excess of 13,000¹, the number of contract development and manufacturing organizations (CDMOs) has also significantly increased. With more CDMOs to choose from, pharmaceutical companies must prioritize CDMO selection criteria to find the right partner for their new drug development project.

With many molecules and new drugs failing, concurrently testing multiple drugs is crucial to success and the reason why many pharmaceutical companies use CDMOs. Developing a new drug takes time—an average of 10 to 12 years—and can cost upward of $5.5 billion dollars, making the selection of the right CDMO critical.

CDMO Selection Criteria: Finding the Right Partner

Consider the following CDMO selection criteria to ensure your choice of CDMO is based on the strategy of the project and the needs of your pharmaceutical company:

1. Your Drug’s Development Stage. The stage of your drug development is likely a key deciding factor for whether or not a sponsor will move forward with a CDMO rather than keep it in house. Know what questions to ask and details to share with your CDMO to get a proper estimate, set clear expectations and develop a realistic timeline.
2. Range of Services. It’s important to understand your company’s approach to outsourcing, or, if this is your first time considering a CDMO partner, to begin outlining your expectations for using a CDMO. Does all outsourcing need to happen with one vendor, or can various CMOs, CDMOs and CROs assist in bringing your new drug to the marketplace?
3. Transparency regarding costs. With the median final cost of bringing a new drug to market sitting at 985 million getting an accurate outline of expected costs is crucial to keeping development and manufacturing costs in check.
4. Speed and Quality of development and production. Your timeline and the desired speed-to-market is a key consideration in choosing a CDMO, but not at the cost of sacrificing quality.

Your Drug’s Development Stage

Will you be working with a CDMO for discovery and drug development all the way through approvals and commercialization? Will your work with a CDMO for commercial manufacturing begin with preclinical development or with clinical research?

Selecting the right CDMO partner depends heavily on the stage of drug development the sponsor is in.

• Discovery: Defining the disease or condition you are targeting and identifying the biochemical mechanism that will best treat it is first. Drug candidates are then tested for their interaction with the disease or condition they are meant to treat, and primary compounds are identified.

• Development: The development of a new drug includes product characterization, such as molecule size and shape, as well as strengths and weaknesses (function, toxicity, bioactivity and bioavailability). The formulation, delivery method and package development, must also be defined, including the dosage amount, storage and shipment factors and packaging impacts, including heat, light and time, as well as extractable and leachable studies. Other development considerations include pharmacokinetics and drug disposition, preclinical toxicology testing and IND application, bioanalytical testing, and clinical trials (Phase I, II and III).

• Regulatory review and approval. Sending data for your new drug on to regulatory review is a key step in drug development—one that is made easier when you work with a CDMO with rigorous data management protocols in place to show your product meets safety, efficacy and quality standards.

• Commercialization and marketing. After your product is approved, will your CDMO be able to scale up production from development and testing into commercialization, or will you need to work with another partner to bring your new product to market?

The stage of your drug development will impact the amount of material needed, which may impact the choice of CDMO based on their capacity and facility space to produce the desired amount. In addition, an experienced CDMO can help you gain a better understanding of an achievable timeline based on factors for cGMP manufacturing and beginning clinical trials.

Range of Services

According to Industry Standard Researcher’s development and commercial outsourcing models sponsors indicated preference for using the same CDMO for development and commercial manufacturing. It is imperative for sponsors to define whether or not every phase of drug development, testing, approval, and manufacture needs to live with a single CDMO.

Using an all-in-one CDMO has its advantages, such as improved communication with fewer players to transition details to and better timeline management with less risk for overlap when moving from one vendor/stage to the next. Though, sometimes using a single CDMO for your new drug development and manufacturing isn’t possible due to a variety of constraints, such as capacity and availability during certain stages of development, and the flexibility needed to adapt quickly to meet Phase I timelines. Keep in mind that if you use more than one CDMO, you may be required to pay royalties to transfer from one CDMO to another, so be sure to factor those costs into your total new drug development costs.

Review the stages of development and identify which stages will stay in house and which ones will be outsourced and to whom:

• Pre-formulation

• Formulation development

• Stability studies

• Method development

• Pre-clinical and Phase I clinical trial materials

• Late-stage clinical trial materials

• Formal stability

• Registration batches

• Commercial production

Don’t forget to evaluate the technology and science needed for your new drug development and determine whether or not your potential CDMO partner has experience in the formulation technologies you need.

Transparency regarding costs.

Your selection of a CDMO based on its range of services and how much of your new drug development you have with one vendor may help keep your costs lower, but may not be possible due to time constraints. When you receive final cost calculations from potential CDMOs, be sure to ask if their final figures include estimated out-of-pocket expenses and capitalized costs.

Keep in mind that drug development processes may vary significantly due to findings in early-stage drug development and results from clinical trials. This makes drug development costs highly unpredictable, and the use of an experienced CDMO even more crucial to keeping costs in check.

Work with your procurement team to develop a checklist of questions to ask your potential CDMO partner, including whether or not you need to pay royalties when the project transitions from one CDMO partner to another, how they handle scope changes and whether or not they proactively share costs associated with scope changes, re-work due to molecule failures in early-stage testing, etc. and their overall approach to providing open-ended communication regarding expenses and expectations.

Speed and Quality of Development and Production

When you are launching a new drug with the goal of speed-to-market or being first-to-market, working with an experienced CDMO can be the difference between making it to market on time or not making it at all.

Be sure to ask about and get a good picture of your potential CDMO partner’s availability and capacity right now, as well as their current experience and capabilities. Identify any changeovers or transfer of information, data, processes and new setup time if you are using more than one CDMO vendor.

A CDMO who has experience working with a wide array of molecules and for various pharmaceutical companies can help identify potential issues or watchouts as you develop processes or scale up, and can use design of experiments (DoE) techniques during process design to reduce risks as your new drug development progresses. Experienced CDMOs also tend to have stronger scientific and technical teams (such as for complex injectables development and manufacture) who use their expertise to advance your drug to the next stage, as well as the technologies and facilities equipped to handle your specific drug development processes. Don’t be afraid to talk to the CDMO’s current clients, consultants and colleagues to get to know the CDMO’s working style and potentially identify any issues in quality.

Choosing the Right CDMO is Vital to the Success of Your Project

Ascendia Pharmaceuticals is a CDMO that specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies. Providing formulation, analytical, and manufacturing services to pharmaceutical companies, we work collaboratively with drug sponsors to provide innovative solutions to challenging drug delivery problems and to create advanced medicines.

Our technologies include nano-emulsions, amorphous solid dispersions, oral controlled release, self-emulsifying drug delivery systems (SEDDs) and production of nano-particles. Ascendia provides development and testing services—from pre-formulation through to manufacture of pilot clinical supplies.

As a specialty CDMO, Ascendia offers expertise in a wide variety of development programs. We have the capability to work on early-stage formulations of programs as diverse as peptides, high-potency molecules, nano-particles, animal health products, and parenteral dosage forms.

Ascendia Pharmaceuticals provides its partners with complete CDMO services from pre-formulation to clinical manufacture. Contact us today to learn more.

References

Want more information on Pharmaceutical Intermediate Service? Feel free to contact us.